VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
HUIZ
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HUIZHuize Holding Limited
$1.14$575220
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksHUIZFinancials

Huize Holding Limited (HUIZ) Financials

9Y historyFree accessUpdated daily

The company exhibits highly inconsistent top-line performance, evidenced by a 40.2% revenue growth in 2025Q2 following a period of contraction, while underwriting profitability remains precarious with a combined ratio that fluctuated to 103.3% in 2025Q1.

HUIZ Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17
Revenue1.34B1.54B1.25B1.2B1.16B2.25B1.22B993.32M508.83M263.33M
Revenue Growth %19.12%23.24%4.46%3.25%-48.42%83.98%22.84%95.22%93.23%-
Medical Costs & Claims951.98M1.12B868.29M729.07M734.29M1.69B816.35M631.37M318.3M166.67M
Medical Cost Ratio %71.25%72.93%69.52%60.98%63.42%75.31%66.9%63.56%62.56%63.29%
Gross Profit384.2M416.69M380.63M466.48M423.62M554.26M403.87M361.95M190.53M96.66M
Gross Margin %28.75%27.07%30.48%39.02%36.58%24.69%33.1%36.44%37.44%36.71%
Gross Profit Growth %-9.47%-18.4%10.12%-23.57%37.24%11.58%89.97%97.1%-
Operating Expenses383.15M410.22M401.58M415.44M467.29M668.67M429.78M360.31M165.73M196.96M
OpEx / Revenue %28.68%26.65%32.15%34.75%40.36%29.78%35.22%36.27%32.57%74.8%
Depreciation & Amortization3.41M23.03M36.27M13.64M18.43M7.42M5.11M3.78M3.08M3.56M
Combined Ratio %99.92%99.58%101.68%95.73%103.77%105.1%102.12%99.83%95.13%138.09%
Operating Income1.05M6.47M-20.96M51.04M-43.67M-114.41M-25.91M1.64M24.79M-100.3M
Operating Margin %0.08%0.42%-1.68%4.27%-3.77%-5.1%-2.12%0.17%4.87%-38.09%
Operating Income Growth %-130.89%-141.06%216.87%61.83%-341.55%-1680.9%-93.39%124.72%-
EBITDA4.46M29.5M15.31M64.68M-25.25M-106.99M-20.8M5.42M27.87M-96.74M
EBITDA Margin %0.33%1.92%1.23%5.41%-2.18%-4.77%-1.7%0.55%5.48%-36.74%
Interest Expense000630K5.06M3.21M1.16M190K27.11M0
Non-Operating Income0-3.97M00000-13.76M-4.21M-2.67M
Pretax Income16.85M10.44M701K70.55M-33.74M-107.72M-16.52M15.03M3.21M-96.64M
Pretax Margin %1.26%0.68%0.06%5.9%-2.91%-4.8%-1.35%1.51%0.63%-36.7%
Income Tax1.6M7M135K0001.77M57K278K406K
Effective Tax Rate %9.51%67.04%19.26%0%0%0%-10.7%0.38%8.67%-0.42%
Net Income18.08M3.93M-649K70.19M-31.19M-107.67M-18.29M14.9M3.15M-97.17M
Net Margin %1.35%0.26%-0.05%5.87%-2.69%-4.8%-1.5%1.5%0.62%-36.9%
Net Income Growth %-16.73%705.54%-100.92%325.06%71.03%-488.6%-222.75%372.78%103.24%-
EPS (Diluted)35.847.80-1.28140.00-5.40-32.60-7.605.801.38-87.20
EPS Growth %265.31%709.38%-100.91%2692.59%83.44%-328.95%-231.03%320.29%101.58%-
EPS (Basic)-7.80-1.28140.00-5.40-34.00-7.605.801.39-95.80
Diluted Shares Outstanding504.43K504.58K506.9K2.48M2.55M2.55M2.41M2.57M2.28M1.11M

Key Metrics

Growth RegimeMixed
ProfitabilityStrained
Balance SheetAdequate
Cash FlowMixed
Top Statement Risk

Regulatory commission structure shifts

Volatile Revenue Growth Patterns Observed

As evidenced by the 40.2% revenue surge in 2025Q2 following a contraction in previous periods, Huize's top-line trajectory remains highly inconsistent, reflecting the inherent seasonality and sensitivity of its digital-first brokerage model to shifting consumer demand within the competitive Chinese insurance landscape.

The company's revenue growth appears heavily influenced by the 'Jump Start' sales cycle, yet the lack of sustained momentum suggests difficulty in maintaining consistent customer acquisition. Investors should monitor whether this volatility stems from external market saturation or internal challenges in scaling the influencer-led distribution network.

Underwriting Profitability Remains Precariously Thin

Based on reported financial statements, the combined ratio fluctuated significantly, reaching 103.3% in 2025Q1 before improving to 96.4% in 2025Q2, which highlights the company's struggle to maintain consistent underwriting profitability amidst high variable costs and intense competition for digital traffic.

The oscillation around the 100% combined ratio threshold indicates that Huize frequently operates at an underwriting loss, necessitating extreme efficiency in its expense management. The reliance on third-party traffic sources appears to create a structural ceiling on margin expansion that may persist without a shift toward lower-cost direct acquisition.

Operational Friction During Market Transitions

According to recent quarterly data, the transition between 2024Q4 and 2025Q1 marked a period of significant operational stress, where the combined ratio spiked to 103.3%, suggesting that regulatory or competitive pressures may be disproportionately impacting the company's ability to convert premiums into sustainable operating income.

This inflection point underscores the vulnerability of the brokerage model to sudden changes in fee-and-rate matching regulations. The subsequent recovery in 2025Q2 warrants further investigation into whether this was driven by structural improvements or merely a temporary rebound in seasonal policy volume.

Sustainability of Commission-Based Revenue Model

While Huize reports top-line growth, the persistent volatility in net income, which swung from a $23.3M loss in 2024Q2 to a $10.9M profit in 2025Q2, suggests that the underlying quality of earnings may be compromised by high acquisition costs and potential reliance on non-recurring revenue streams.

The reliance on contract assets for future renewal commissions may mask underlying lapse risks, particularly if economic conditions in China pressure policy persistency. Analysts should remain cautious regarding the potential for future impairments if the actual renewal experience deviates from the actuarial assumptions currently embedded in the balance sheet.

HUIZ — Frequently Asked Questions

Quick answers to the most common questions about buying HUIZ stock.

What was Huize Holding Limited's (HUIZ) revenue in 2025?

For fiscal year 2025, Huize Holding Limited (HUIZ) reported total revenue of $1.54B. This represents a 484.5% increase compared to $263.3M in 2017.

Is Huize Holding Limited (HUIZ) profitable?

Huize Holding Limited (HUIZ) is profitable, generating $3.9M in net income for the fiscal year ending 2025 with a net profit margin of 0.3%.

What is Huize Holding Limited's operating profit margin?

Huize Holding Limited (HUIZ) reported an operating income of $6.5M, resulting in an operating profit margin of 0.4%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Huize Holding Limited's gross profit and gross margin?

Huize Holding Limited (HUIZ) generated $416.7M in gross profit for the year, representing a gross profit margin of 27.1%. This demonstrates the company's core pricing power and production efficiency.